These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25800075)

  • 1. Prevalence of CYP2C19 alleles, pharmacokinetic and pharmacodynamic variation of clopidogrel and prasugrel in Bangladeshi population.
    Bin Sayeed MS; Hasan Apu MN; Munir MT; Ahmed MU; Islam MS; Haq MM; Ahsan CH; Rashid MA; Shin JG; Hasnat A
    Clin Exp Pharmacol Physiol; 2015 May; 42(5):451-7. PubMed ID: 25800075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
    Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
    Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
    Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
    Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
    J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
    Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
    Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
    Jin C; Kim MH; Guo LZ; Jin E; Shin ES; Ann SH; Cho YR; Park JS; Kim SJ; Lee MS
    Int J Cardiol; 2020 Apr; 305():11-17. PubMed ID: 32029306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
    Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
    JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
    Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
    J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
    Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
    Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.
    Erlinge D; James S; Duvvuru S; Jakubowski JA; Wagner H; Varenhorst C; Tantry US; Brown PB; Small D; Moser BA; Sundseth SS; Walker JR; Winters KJ; Gurbel PA
    Thromb Haemost; 2014 May; 111(5):943-50. PubMed ID: 24402637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
    J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.